Pacira BioSciencesFRA:82P +6.74%74 OCF Margin % is 14.48% as of Mar. 2026, which is 25% below its 10-year median of 19.43. GuruFocus rates FRA:82P with a GF Score™ of 74/100 and a GF Value™ of €24.22. The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Pacira BioSciences ranks better than 76.54% on this metric.
The historical rank and industry rank for Pacira BioSciences's OCF Margin % or its related term are showing as below:
FRA:82P'
s OCF Margin % Range Over the Past 10 Years
Min: 6.2 Med: 19.43 Max: 27.02
Current: 19.28
During the past 13 years, the highest OCF Margin % of Pacira BioSciences was 27.02%. The lowest was 6.20%. And the median was 19.43%.
FRA:82P's OCF Margin % is ranked better than 76.54% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs FRA:82P: 19.28
Pacira BioSciences OCF Margin % Related Terms
Pacira BioSciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, ESPR: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a OCF Margin % of 14.48% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pacira BioSciences and its competitors. This is 25% below median its historical median of 19.43. Over the past decade, Pacira BioSciences' OCF Margin % has ranged from 6.20 to 27.02. According to the industry distribution chart, Pacira BioSciences ranks #225 out of 959 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Pacira BioSciences' OCF Margin % too high?
Pacira BioSciences' current OCF Margin % of 14.48% is 25% below median its 10-year median of 19.43. Over the past 10 years, this metric has ranged from a low of 6.20 to a high of 27.02. The Drug Manufacturers industry median OCF Margin % is 9.95. Pacira BioSciences' value of 14.48% is 45.5% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #225 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' OCF Margin % compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #225 out of 959 companies for OCF Margin %. This places Pacira BioSciences in the top 24% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Pacira BioSciences' value of 14.48% is 45.5% above this benchmark. Historically, Pacira BioSciences' own OCF Margin % has ranged from 6.20 to 27.02 over the past decade. While the company's 10-year median is 19.43 vs. the industry median of 9.95, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current OCF Margin % of 14.48% is 45.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current OCF Margin % is 14.48%, which is 25% below median its own 10-year median of 19.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current OCF Margin % of 14.48%. The stock's GF Value™ is €24.22, compared to a current price of €20.60 — trading 14.9% below its estimated fair value. The current OCF Margin % is 14.48%, which is 25% below median its 10-year median of 19.43 and 45.5% above the Drug Manufacturers industry median of 9.95. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current OCF Margin % is 14.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €20.60 is trading 14.9% below its estimated GF Value™ of €24.22.
Key valuation signals for FRA:82P:
OCF Margin %: 14.48% (25% below median its 10-year median of 19.43)
GF Value™: €24.22 vs. price of €20.60 (14.9% below fair value)
Industry Position: 45.5% above the Drug Manufacturers median (#225 of 959)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score
Get the complete analysis for FRA:82P
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
